Immune-mediated necrotizing myopathy with pembrolizumab: a specific neuromuscular entity
- 6 January 2022
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (4) , 687-690
Abstract
Purpose Pembrolizumab is a humanized monoclonal antibody that binds to the programmed cell-death protein-1 (PD-1) on immune T-cells, thus blocking PD-1 activity. Pembrolizumab is indicated for the treatment of advanced melanoma, metastatic non-small-cell lung cancer, and head and neck squamous cell carcinoma. However, it is associated with immune-related adverse events. Methods We investigated the association between pembrolizumab and immune-mediated necrotizing myopathy (IMNM). We analyzed reports in the World Health Organization’s global individual case safety report database, Vigibase, up to January 2020 with the MedDRA lower level term “IMNM.” The association between exposure to pembrolizumab and occurrence of the adverse event was estimated by disproportionality analysis. The reporting odds ratio (ROR) was calculated with 95% confidence intervals (CIs). We analyzed the criteria of diagnosis of the adverse reaction. Results Five-hundred sixty-seven notifications were identified as IMNM of which 14 with pembrolizumab. The ROR was 17.59 (95% CI: 9.4–32.9). Conclusion The diagnosis of IMNM does not always take into account recent criteria for the diagnosis of this pathology. This study highlights the existence of a signal, as well as the need for collaboration between oncologists and neurologists for these neurological pathologies.Keywords
This publication has 15 references indexed in Scilit:
- PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated MyopathiesJournal of Immunotherapy, 2018
- 224th ENMC International Workshop:Neuromuscular Disorders, 2018
- Pathogenic role of anti–signal recognition protein and anti–3‐Hydroxy‐3‐methylglutaryl‐CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathiesAnnals of Neurology, 2017
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint InhibitorsJAMA Oncology, 2016
- Statin-Associated Autoimmune MyopathyNew England Journal of Medicine, 2016
- Myasthenia gravis: subgroup classification and therapeutic strategiesThe Lancet Neurology, 2015
- Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities2015
- Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statinsJoint Bone Spine, 2014
- Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohortsMuscle & Nerve, 2011
- Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathyArthritis & Rheumatism, 2010